DOCSLIB.ORG

Proposal for Crossmatch Project 18.10.12.Docx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proposal for Crossmatch Project 18.10.12.Docx Aus der Klinik für kleine Haustiere des Fachbereichs Veterinärmedizin der Freien Universität Berlin Studies in feline pre-transfusion testing: Evaluating a novel blood typing device and serial cross-matching in transfusion patients Inauguraldissertation zur Erlangung des Grades eines Doktors der Veterinärmedizin an der Freien Universität Berlin Vorgelegt von Layla Hourani Tierärztin aus Rostock Berlin 2017 Journal-Nr.: 3990 Gedruckt mit Genehmigung des Fachbereichs Veterinä rmedizin der Freien Universitä t Berlin Dekan: Univ.-Prof. Dr. Jürgen Zentek Erster Gutachter: Univ.-Prof. Dr. Barbara Kohn Zweiter Gutachter: Univ.-Prof. Dr. Heidrun Gehlen Dritter Gutachter: Univ.-Prof. Dr. Robert Klopfleisch Deskriptoren (nach CAB-Thesaurus): blood type, blood typing, cat, cross-matching, pre- transfusion testing, point-of-care, transfusion medicine, transfusion safety Tag der Promotion: 19.07.2017 2 To Friedolin, Krikri, Molly, Spotty and the old gibbon couple at Sababurg Zoo 3 Table of contents LIST OF ABBREVIATIONS.....................................................................................................................6 TABLES AND FIGURES .........................................................................................................................7 1 INTRODUCTION ...........................................................................................................................8 1.1 HISTORY OF TRANSFUSION MEDICINE AND TRANSFUSION SAFETY .......................................................9 1.2 PATIENT SAFETY IN TRANSFUSION MEDICINE ............................................................................... 10 1.2.1 Transfusion reactions ........................................................................................... 10 1.2.2 Alloimmunisation ................................................................................................... 14 1.2.3 Strategies to reduce the risks associated with transfusions .............................. 15 1.3 CONSIDERATIONS SPECIFIC TO FELINE TRANSFUSION MEDICINE ....................................................... 18 1.3.1 Feline blood types ................................................................................................. 19 1.3.2 Feline blood donors .............................................................................................. 22 1.3.3 Blood typing in cats ............................................................................................... 23 1.3.4 Cross-matching in cats ......................................................................................... 26 1.4 SIGNIFICANCE OF THE WORK DESCRIBED HERE ............................................................................. 26 2 PUBLICATION I ........................................................................................................................... 27 EVALUATION OF A NOVEL FELINE AB BLOOD TYPING DEVICE........................................................................ 28 2.1 ABSTRACT ........................................................................................................................... 28 2.2 INTRODUCTION .................................................................................................................... 29 2.3 MATERIALS AND METHODS ..................................................................................................... 29 2.3.1 Blood samples ....................................................................................................... 29 2.3.2 Typing methods and equipment .......................................................................... 30 2.3.3 Statistical analysis ................................................................................................. 31 2.4 RESULTS ............................................................................................................................. 32 2.4.1 Blood samples ....................................................................................................... 32 2.4.2 TUBE and GEL test .............................................................................................. 32 2.4.3 IC test ..................................................................................................................... 32 2.5 DISCUSSION ........................................................................................................................ 33 2.6 CONCLUSIONS ..................................................................................................................... 48 2.7 FUNDING ............................................................................................................................ 35 2.8 CONFLICT OF INTEREST .......................................................................................................... 35 2.9 TABLES AND FIGURES ............................................................................................................. 36 2.10 REFERENCES ........................................................................................................................ 37 4 3 PUBLICATION II .......................................................................................................................... 39 ALLOIMMUNISATION IN TRANSFUSED PATIENTS: SERIAL CROSS-MATCHING IN A POPULATION OF HOSPITALISED CATS ………………………………………………………………………………………………………………………………………..40 3.1 ABSTRACT ........................................................................................................................... 40 3.2 INTRODUCTION .................................................................................................................... 41 3.3 MATERIALS AND METHODS ..................................................................................................... 42 3.3.1 Study population.................................................................................................... 42 3.3.2 Transfusions and pre-transfusion testing ............................................................ 42 3.3.3 Cross-matching ..................................................................................................... 43 3.3.4 Statistical analysis ................................................................................................. 44 3.4 RESULTS ............................................................................................................................. 44 3.5 DISCUSSION ........................................................................................................................ 46 3.6 CONCLUSIONS ..................................................................................................................... 48 3.7 ACKNOWLEDGEMENTS .......................................................................................................... 49 3.8 FUNDING ............................................................................................................................ 49 3.9 CONFLICT OF INTEREST .......................................................................................................... 49 3.10 TABLES ............................................................................................................................... 49 3.11 REFERENCES ........................................................................................................................ 51 4 DISCUSSION ............................................................................................................................... 27 4.1 FINDINGS ............................................................................................................................ 54 4.1.1 Evaluation of a novel feline AB blood typing device .......................................... 44 4.1.2 Alloimmunisation in transfused cats .................................................................... 57 4.2 LIMITATIONS ....................................................................................................................... 58 4.2.1 Evaluation of a novel feline AB blood typing device .......................................... 58 4.2.2 Alloimmunisation in transfused cats .................................................................... 59 4.3 SUGGESTIONS FOR FUTURE RESEARCH ....................................................................................... 59 4.4 CONCLUSIONS ..................................................................................................................... 61 5 SUMMARY ................................................................................................................................. 62 6 ZUSAMMENFASSUNG ................................................................................................................ 64 7 BIBLIOGRAPHY ........................................................................................................................... 66 8 LIST OF PUBLICATIONS ............................................................................................................... 76 9 ACKNOWLEDGEMENTS .............................................................................................................. 77 10 DECLARATION OF INDEPENDENT SCHOLARSHIP ........................................................................ 78 5 List of abbreviations ABCD (European) Advisory Board on Cat Diseases ACD Acid citrate dextrose BT Blood transfusion BSAVA British Small Animal Veterinary Association cDNA Complementary DNA CM Cross-match CMAH
Load more

Recommended publications
  • Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver
    Confidential Page 1 of 80 Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver Transplantation Version 7.0/ August 1, 2018 IND# 15479 Study Sponsor(s): The National Institute of Allergy and Infectious Diseases (NIAID) Grant #: R34AI095135 and U01AI110658-01 Study Drug Manufacturer/Provider: Sanofi US PRINCIPAL INVESTIGATOR CO- PRINCIPAL INVESTIGATOR CO- PRINCIPAL INVESTIGATOR SANDY FENG, MD, PHD JEFFREY BLUESTONE, PHD SANG-MO KANG, MD, FACS Professor of Surgery Executive Vice Chancellor and Provost Associate Professor Director, Abdominal Transplant A.W. Clausen Distinguished Professor University of California, San Surgery Fellowship in Medicine Francisco University of California, San University of California, San Francisco 513 Parnassus Ave. Francisco 513 Parnassus Ave. Box 0780, HSE-520 505 Parnassus Ave. Box 0400, HSW-1128 San Francisco, CA 94143-0780 Box 0780, M-896 San Francisco, CA 94143-0780 Phone: (415) 353-1888 San Francisco, CA 94143-0780 Phone: (415) 476-4451 E-mail: Sang- Phone: (415) 353-8725 Fax: (415) 476-9634 [email protected] Fax: (415) 353-8709 E-mail: [email protected] E-mail: [email protected] CO- PRINCIPAL INVESTIGATOR BIOSTATISTICIAN MEDICAL OFFICER QIZHI TANG, PHD DAVID IKLÉ, PHD NANCY BRIDGES, MD Associate Professor Senior Statistical Scientist Chief, Transplantation Branch Director, UCSF Transplantation Rho, Inc. Division of Allergy, Immunology, Research Lab 6330 Quadrangle Drive and Transplantation University of California, San Chapel Hill, NC 27517 NIAID Francisco Phone: (910) 558-6678
    [Show full text]
  • Java Based Distributed Learning Platform
    Journal of Pharmacy and Pharmacology 8 (2020) 110-123 doi: 10.17265/2328-2150/2020.04.003 D DAVID PUBLISHING Blood Group Cartography (ABO, RHESUS, KELL and DUFFY) and Hemogram of Icteric Newborn in Sendwe Hospital, Lubumbashi/D.R.C Monga Kalenga J. J1, Monga Ngoy Davidson2, Matanda Kapend Serge3, Masendu Kalenga Paulin4, Haumont Dominique5 and Luboya Numbi Oscar1 1. Department of Pediatrics, Faculty of Medicine, University of Lubumbashi, Haut-Katanga 1825, DRC. 2. Laboratory Department Head Sendwe Hospital, Haut Katanga, Lubumbashi 1825, DRC 3. Department of Internal Medicine, Faculty of Medicine, University of Lubumbashi, Haut-Katanga 1825, DRC. 4. CHR The Citadel, Neonatology Department, University of Liège, Liège 4450, Belgium. 5. Free University of Brussels, Brussels 1050, Belgium Abstract: Background: Allo immunization jaundice is a common cause of neonatal jaundice. According to racial group the concerned blood group may not be the same. In our Country people are exposed to high transfusionnal risk because of malaria and sicklanemia and the blood group research in laboratory include only ABO/D. Objective: Our objective was to establish a blood group cartography of this icteric newborn population and their mother; the frequency of rare blood group and the compatibility level between mother and newborn. Our interest was also to study hemogram of this population. Methodology: We studied blood group ABO/D; RH/Kell and Duffy of 56 newborn whom developped an indirect bilirubin and their mothers. We performed bilrubin level and hemogram. Results: The frequency of icteric newborn was 17.17%. The mother blood mapping was O (60.71%), RhD positive (83.9%), C negative (91.07%) E negative (89.29%) c positive (91.07%), epositive (92.86%), kell negative (100%) and duffy null (100%).
    [Show full text]
  • Humoral Alloimmunity in Cardiac Allograft Rejection
    Humoral alloimmunity in cardiac allograft rejection Jawaher Alsughayyir Darwin College Department of Surgery University of Cambridge This dissertation is submitted for the degree of Doctor of Philosophy July 2018 i Declaration This dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration except where declared in the text. It has not been submitted in whole or part for a degree at any university. The length of this thesis does not exceed the 60,000 word limit i Dissertation title: Humoral alloimmunity in cardiac allograft rejection Student name: Jawaher Alsughayyir Abstract Although the short-term outcomes of solid allograft survival have improved substantially over the last few decades, there has been no significant improvement in long-term survival of solid allografts. This thesis presents the initial characterisation of alloantibody mediated rejection in a murine heart transplant model, with particular focus on the impact of the different phases of the humoral alloimmune response (follicular or germinal centre) on graft rejection. The key findings of this work are: 1) The precursor frequency of allospecific CD4 T cells determines the magnitude of the alloantibody response, with a relatively high frequency of CD4 T cells eliciting strong extrafollicular responses, while a high frequency of B cells promotes slowly-developing germinal centre responses. 2) Strong extrafollicular antibody response can mediate acute heart allograft rejection in the absence of CD8 T cells alloresponses. 3) Germinal centre humoral immunity mediates chronic antibody-mediated rejection. 4) Recipient memory, but not naïve, CD4 T cells that recognise one graft alloantigen can provide ‘unlinked’ help to allospecific B cells that recognise a different graft alloantigen for generating germinal centre alloantibody responses.
    [Show full text]
  • Neonatal Isoerythrolysis Neonatal Isoerythrolysis Pathogenesis
    Neonatal Isoerythrolysis Neonatal Isoerythrolysis Pathogenesis Immune mediated hemolytic anemia Mediated by maternal anti-RBC antibodies Colostrum Neonatal Isoerythrolysis Pathogenesis Foal inherits specific RBC Ag from the sire Dam does not have these Ag Dam previously sensitized Placental bleeding - previous pregnancies Previous whole blood transfusion Equine biologics Plasma contaminated with RBC Ag Neonatal Isoerythrolysis Pathogenesis Current pregnancy mare re-exposed Mounts antibody response Concentrates antibodies in colostrum Foal absorb the colostral Abs Hemolytic Anemia Neonatal Isoerythrolysis Pathogenesis 32 blood group antigens in horses Aa and Qa 90% of the reactions R and S groups most of the rest Based on gene frequencies TB, QH, Saddlebred, - Qa & Aa Standardbred, Morgan - Aa (not Qa) Arabian - Qa Neonatal Isoerythrolysis Clinical signs Onset 8-120 hours old Depends on amount of antibody absorbed Titer in colostrum Amount ingested More antibody absorbed More rapid the onset More severe the disease Neonatal Isoerythrolysis Peracute disease Severe, acute anemia (massive hemolysis) No hypoxemia Tissue hypoxia Metabolic acidosis MODS Neonatal Isoerythrolysis Peracute disease Normal at birth Sudden onset Weakness Tachycardia Tachypnea Collapse Neonatal Isoerythrolysis Peracute disease Neurologic derangement Fever or hypothermia Cardiovascular collapse Shock Death - often before icteric Neonatal Isoerythrolysis Acute disease Normal at birth Progressive weakness Icterus (may become
    [Show full text]
  • Occurrence, Hematologic and Serum Biochemical Characteristics of Neonatal Isoerythrolysis in Arabian Horses of Iran
    Archive of SID Original Paper DOI: 10.22067/veterinary.v1-2i10-11.71821 Received: 2018-Mar-27 Accepted after revision: 2018-Aug-07 Published online: 2018-Sep-26 Occurrence, hematologic and serum biochemical characteristics of neonatal isoerythrolysis in Arabian horses of Iran a a a Seyedeh Missagh Jalali, Mohammad Razi-Jalali, Alireza Ghadrdan-Mashhadi, b Maryam Motamed-Zargar a Department of Clinical Sciences, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran b Graduated student of Veterinary Medicine, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran Keywords assessment, the foal with hemolytic anemia showed neonatal isoerythrolysis, hemolytic anemia, Arabian horses, a major decline in hematocrit, hemoglobin concen- Khouzestan tration and erythrocyte count along with considerable leukocytosis and neutrophilia. Serum total and direct Abstract bilirubin concentrations in the NI case was about ten times higher than in the rest of the foals. This study Neonatal isoerythrolysis is a major cause of ane- revealed that neonatal isoerythrolysis can occur in Arabian mia in newborn foals. However, there are no docu- foals of Khouzestan and is associated with severe anemia mented data regarding the occurrence of neonatal and icterus which may lead to death. These findings can be isoerythrolysis in Arabian horses of Iran, which are beneficial in the establishment of preventive measures in mostly raised in Khouzestan province. Hence, this Arabian horse breeding industry in the region, as well as study was carried out to investigate the occurrence of improving therapeutic methods. neonatal isoerythrolysis in Arabian horses of Khou- zestan and assess the hematologic and serum bio- chemical profile of affected foals.
    [Show full text]
  • Investigation of Penicillamine-Induced Autoimmunity
    Mechanistic Investigation of Penicillamine-Induced Autoimmunity: Covalent Binding of Penicillamine to Macrophages, Involvement of Th17 cells, and Its Relation to Idiosyncratic Drug-induced Liver Injury By Jinze Li A thesis submitted in conformity with the requirements for the degree of DOCTOR OF PHILOSOPHY Graduate Department of Pharmaceutical Sciences University of Toronto ©Copyright by Jinze Li 2009 Library and Archives Bibliothèque et Canada Archives Canada Published Heritage Direction du Branch Patrimoine de l’édition 395 Wellington Street 395, rue Wellington Ottawa ON K1A 0N4 Ottawa ON K1A 0N4 Canada Canada Your file Votre référence ISBN: 978-0-494-61128-9 Our file Notre référence ISBN: 978-0-494-61128-9 NOTICE: AVIS: The author has granted a non- L’auteur a accordé une licence non exclusive exclusive license allowing Library and permettant à la Bibliothèque et Archives Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par télécommunication ou par l’Internet, prêter, telecommunication or on the Internet, distribuer et vendre des thèses partout dans le loan, distribute and sell theses monde, à des fins commerciales ou autres, sur worldwide, for commercial or non- support microforme, papier, électronique et/ou commercial purposes, in microform, autres formats. paper, electronic and/or any other formats. The author retains copyright L’auteur conserve la propriété du droit d’auteur ownership and moral rights in this et des droits moraux qui protège cette thèse. Ni thesis. Neither the thesis nor la thèse ni des extraits substantiels de celle-ci substantial extracts from it may be ne doivent être imprimés ou autrement printed or otherwise reproduced reproduits sans son autorisation.
    [Show full text]
  • Molecular Identification of T Cells That Respond in a Primary Bulk Culture
    Molecular Identification of T Cells That Respond in a Primary Bulk Culture to a Peptide Derived from a Platelet Glycoprotein Implicated in Neonatal Alloimmune Thrombocytopenia Krystyna Maslanka, Maryam Yassai, and Jack Gorski Immunogenetics Research Section, Blood Research Institute, The Blood Center of Southeastern Wisconsin, Milwaukee, Wisconsin 53201-2178 Abstract Among these, the platelet alloantigen system associated with surface integrin GPIIb/IIIa (␣IIb␤3) plays an important role in Neonatal alloimmune thrombocytopenia induced by the hu- pregnancy and transfusion related alloimmunity (1, 2). man platelet alloantigen 1a (HPA1a) is characterized by A characteristic of these alloimmune responses is the pres- generation of alloantibodies by a mother who is homozy- ence of circulating antibodies specific for the alloantigen. These gous for the HPA1b alloantigen and almost always HLA- are thought to mediate the destruction of the cells expressing DRB3*0101. The disease is viewed as B cell mediated but the alloantigen. One particular alloimmune response is inter- the linkage with HLA is indicative of a role for T cells. The esting in its HLA restriction. The GPIIb/IIIa alloantigens HPA1a and HPA1b allotypes are defined, respectively, by HPA1a and HPA1b are defined by antibodies which are sensi- Leu and Pro at amino acid 33 of the ␤-chain of the platelet tive to the polymorphism at position 33 of the GPIIIa chain integrin GPIIbIIIa (␣IIb␤3). Under the assumption that the (3). Mutagenesis experiments have shown that this polymor- same polymorphism may control both the B cell epitope and phism is sufficient for inducing alloantibody recognition (4). constitute the MHC-bound peptide, we restimulated PBMC The generation of a response to HPA1a (GPIIIaLeu33) requires from a woman with an affected child with a synthetic pep- that the responder be HPA1b (GPIIIaPro33) homozygous.
    [Show full text]
  • Dr* Robert Hillman Cares for a Newborn with Assistance from Judy Chapman
    Dr* Robert Hillman cares for a newborn with assistance from Judy Chapman. DO YOU HAVE A 'PREEMIE1? The perinatal period for the equine has been defined as the period from Day 300 of gestation, generally considered to be the lowest By Pamela Livesay-Wilkins '86 limit of viability, to 96 hours post-partum, "ith Special Thanks to Dr. Diane Craig when the foal is considered to have reached a steady state of body functions, recovering from the stresses of birth. Events in the fetus and in the mother need to be closely coordinated so There are times when the mother and the that the mother will give birth to a full-term, ^ tus are prepared for birth at different stages mature foal that is capable of survival outside ?f gestation. When it happens that the mother the uterus. However, there are a variety of ls ready first, the foal may be born premature. conditions that can occur and indicate that the Approximately 1% of all Thoroughbreds are mother and fetus were not equally prepared for “orn prematurely, and the incidence approaches birth. Most forms of prematurity have a this value in most other breeds, so it isn't common cause with abortion and the distinction surprising that most active horse breeders have between them is rather arbitrary, based t° deal with the problem of a premature foal at primarily on the prospect for fetal survival and some point. In the last decade the value of gestational age of the fetus. Chronic placental horses, particularly Thoroughbreds, has insufficiency due to twinning, body pregnancy Increased tremendously, reflected by an (pregnancy located in the body of the uterus increased interest on the part of both the rather than in one of the uterine horns), veterinarian and the client in neonatal critical umbilical cord abnormalities, hydrops of the care and management techniques.
    [Show full text]
  • Immune Approach to Primary Graft Dysfunction
    Immune approach to Primary Graft Dysfunction Ankit Bharat MD FACS Harold & Margaret Method Professor Director, Lung Transplant & ECMO Disclosures None PRIMARY GRAFT DYSFUNCTION • Incidence >50-70% • Occurs within first 24 hours following transplant • Characterized by respiratory failure • Leading cause of short-term mortality • Predominant risk factor for chronic rejection PGD INDUCES CYTOKINE STORM AND ALLOIMMUNITY Bharat et al, Annals Thor Surg, 2011 Spectrum of PGD Neutrophil-mediated Ischemia- Donor non-classical monocytes allograft injury reperfusion injury Recipient classical monocytes Donor Pneumonia Donor Alveolar Macrophages Donor-specific antibodies Complement activation Antibody-mediated rejection Immune complex deposition Monocyte/macrophage activation (hyperacute/acute) Lung-restricted antibodies Inadequate allograft Endothelial Necroptosis preservation damage NEUTROPHILS MEDIATE PGD Kreisel D et al. J Clin Invest 2011;121:265–276. PERFUSED HUMAN DONOR LUNGS CONTAIN MONOCYTES Bharat et al, AJRCMB, Jan 2016 Zhikun et al, Science Transl Med, 2017 Demonstration of non-classical monocytes in the intravascular space of donor lungs Human Mouse NCM CM Neutrophils n o i s u f r e p e r - e r P n o i s u f r e p e r - t s o P NCM are visualized at sites of neutrophil recruitment and endothelial injury Human PGD LIPOSOMAL CLODRONATE DEPLETES Ly6Clow MONOCYTES IN PERFUSED LUNGS Control Clo-lip 87.1 73.2 12.9 26.5 Flushed Lung Ly6C MHC II Tissue monocytes Patrolling endothelial- bound monocytes Flushed Lung Ly6C MHC II Depletion of donor
    [Show full text]
  • D:\My Documents\Vet Alumnus
    For Private Circulation Only Vol. XXXVIII (No. 2) December, 2016 Vet Alumnus Vol. XXXVII (No. 2) December, 2016 1 ISSN 2319-5762 Editor: Dr. Amarjit Singh Associate Editor: Dr. Jaswinder Singh Vet Alumnus Vol. XXXVII (No. 2) December, 2016 2 CONTENTS 1. SOME ANATOMICAL DIFFERENCES IN STIFLE 1 JOINT OF BUFFALO AND CATTLE VARINDER UPPAL, NEELAM BANSAL, ANURADHA GUPTA AND OPINDER SINGH 2. BUSINESS OPPORTUNITIES FOR VETERINARIANS IN INDIA 5 MK GUPTA AND HK VERMA 3. CLASSICAL SWINE FEVER-DREADLY DISEASE IN PIGS 11 V. MAHAJAN, G. FILIA, M. S. BAL AND AMARJIT SINGH 4. CRYSTALLOID PLUS COLLOID BASED FLUID THERAPY 14 FOR DYSTOCIA AFFECTED BUFFALO SARVPREET SINGH GHUMAN 5. HOW TO PREPARE YOUR DOG FOR A DOG SHOW 16 KIRTI DUA 6. ULTRASONOGRAPHY: A ROBUST TOOL TO IDENTIFY 21 SUB-FERTILITY IN BREEDING BULLS KHUSHPREET SINGH, AJEET KUMAR AND BILAWAL SINGH 7. LAMENESS IN YOUNG DOGS 24 VANDANA SANGWAN AND YASEEN MOHD SHEIKH JANI 8. PHYSICAL OCCUPATIONAL HEALTH HAZARDS IN VETERINARY 27 PRACTICE AND THEIR MANAGEMENT RAJESH KASRIJA AND SIMRANPREET KAUR 9. POLICY AND STRATEGY FOR GENETIC IMPROVEMENT OF 32 DAIRY ANIMALS IN PUNJAB SIMARJEET KAUR, P.K. SINGH* AND P.S. BRAR 10. A BRIEF INTRODUCTION ON BLOOD GROUPS IN EQUINES 41 AND NEONATAL ISOERYTHEOLYSIS. RABYIAJAVED, PH.D SCHOLAR Note : Authors are sole responsible for the contents given in articles Vet Alumnus Vol. XXXVII (No. 2) December, 2016 3 SOME ANATOMICAL DIFFERENCES IN STIFLE JOINT OF BUFFALO AND CATTLE VARINDER UPPAL, NEELAM BANSAL, ANURADHA GUPTA AND OPINDER SINGH Department of Anatomy, GADVASU, Ludhiana The stifle joint is the largest and most complex and modified hinge joint.
    [Show full text]
  • HLA Overview
    4/12/2018 American Red Cross HLA Laboratories Playing with Matches Shonna Sims, MBA HLA Director American Red Cross [email protected] I have no real or I have no relevant apparent conflict of financial relationship to interest or other disclose. relationships related to the content of this presentation. American Red Cross 1 HLA Overview • HLA = Human Leukocyte Antigen • HPA = Human Platelet Antigen American Red Cross 2 1 4/12/2018 Human Leukocyte Antigen System • HLA Antigens are found on the surface of both platelets and white cells as well as on other nucleated cells of the body. • Platelets carry Class I HLA antigens and lack Class II antigens. American Red Cross 3 Human Leukocyte Antigen System (Class I Antigens) HLA –A, B, C Found on most body tissue cells Interact with cytotoxic T cells American Red Cross 4 Human Leukocyte Antigen System (Class II Antigens) HLA –DR, DP, DQ Limited Cellular Expression Interact with T-helper cells American Red Cross 5 2 4/12/2018 HLA Antibodies HLA antibodies can cause the destruction of transfused platelets. Sensitization may develop due to: • Pregnancy • Multiple transfusions American Red Cross 6 What about HPA? • Refractoriness can be caused by HPA (platelet glycoprotein) antibodies alone (<6% of patients – although I have seen <1%) or in combination with HLA antibodies (<10%). – Some HPA antibodies do not cause recognizable refractoriness due to low pathogenicity and/or low population antigen frequency (OR low titer)…. American Red Cross 7 What about Class II or Cw – they are on the report… • HLA Class II DR/DQ/DP are mainly of interest for bone marrow or tissue transplants, or disease association (DR).
    [Show full text]
  • Blood Product Administration in Children and Young Adults Likely to Need a Solid Organ Transplant October 2020
    Evidence-Based Care Guideline 50 Blood Product Administration in Children and Young Adults Likely to Need a Solid Organ Transplant October 2020 TARGET POPULATION FOR THE RECOMMENDATION Inclusion Criteria Children and young adults who are likely to require solid organ transplantation: For heart transplant, patients with: • single ventricle physiology • cardiac dysfunction • hypertrophic cardiomyopathy • restrictive heart disease For kidney transplant, patients with: • Chronic Kidney Disease (CKD) stage 3 or higher (estimated GFR of < 60 ml/min/1.73 m2) • on dialysis • under evaluation or waitlisted for kidney transplantation • have received a kidney transplant For liver transplant, patients with: • listed for liver transplantation • having received a liver transplant For lung transplant, patients with: • listed for transplantation • having received a lung transplant For small bowel transplant, patients with: • listed for transplantation • having received a small bowel transplant Exclusion Criteria Bone marrow transplant or hematopoietic stem cell transplant recipients EVIDENCE-BASED CARE RECOMMENDATIONS Clinical Assessment Care Recommendation Statement 1 It is strongly recommended that the theoretical future risk of allosensitization should not Recommendation Strength prevent or delay administration of blood products in patients with life threatening conditions Strong that could be reversed by blood product administration (Local Consensus, 2020 [5]). Care Recommendation Statement 2 It is strongly recommended that the decision to administer blood products consider all Recommendation Strength perceived risks and benefits in each individual patient (Scornik, 2013 [1a]). Strong • Note 1: This includes the risk of allosensitization, which has been associated with longer wait times and increased risk of rejection and mortality in patients who are in need of kidney or heart transplantation (Scornik, 2013 [1a]; McKee, 2018 [3a]; Ibrahim, 2011 [4a]).
    [Show full text]